EXAS•benzinga•
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Summary
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga